VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association (ADA), being held from June 25-29, 2010 in Orlando, Florida.
"VIVUS is pleased to have such a robust presence at this year's ADA annual meeting and to have leading experts in obesity, diabetes and cardiometabolic disease presenting data that we believe further highlight the potential impact Qnexa, if approved, may have on the life-threatening comorbidities associated with obesity," commented Leland Wilson, chief executive officer of VIVUS. "As the rates of obesity and their related illnesses continue to grow, we believe that Qnexa may provide patients and their physicians with a much-needed drug therapy in the treatment of this disease. We value this opportunity for engagement with the medical community to share the Qnexa diabetic and glycemic data with experts in this field."
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options